MRK - Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry | Benzinga
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing Merck & Co (NYSE:MRK) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
Merck & Co Background
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Merck & Co Inc | |||||||
| 141.67 | |||||||
| 8 | |||||||
| 5.29 | |||||||
| 12.22% | |||||||
| $6.96 | |||||||
| $12.23 | |||||||
| 8.89% | |||||||
| Eli Lilly and Co | |||||||
| 130.34 | |||||||
| 65.65 | |||||||
| 22.25 | |||||||
| 19.02% | |||||||
| $3.12 | |||||||
| $7.09 | |||||||
| 25.98% | |||||||
| Novo Nordisk A/S | |||||||
| 48.98 | |||||||
| 43.91 | |||||||
| 17.90 | |||||||
| 24.73% | |||||||
| $36.91 | |||||||
| $55.43 | |||||||
| 22.45% | |||||||
| Johnson & Johnson | |||||||
| 21.69 | |||||||
| 5.02 | |||||||
| 4.29 | |||||||
| 4.69% | |||||||
| $5.68 | |||||||
| $14.87 | |||||||
| 2.34% | |||||||
| AstraZeneca PLC | |||||||
| 39.17 | |||||||
| 6.57 | |||||||
| 5.20 | |||||||
| 5.69% | |||||||
| $4.47 | |||||||
| $10.46 | |||||||
| 16.55% | |||||||
| Novartis AG | |||||||
| 23.85 | |||||||
| 5.40 | |||||||
| 4.56 | |||||||
| 6.23% | |||||||
| $4.66 | |||||||
| $9.02 | |||||||
| 9.71% | |||||||
| GSK PLC | |||||||
| 14.75 | |||||||
| 4.73 | |||||||
| 2.15 | |||||||
| 7.69% | |||||||
| $2.07 | |||||||
| $5.39 | |||||||
| 5.93% | |||||||
| Zoetis Inc | |||||||
| 32.93 | |||||||
| 15.42 | |||||||
| 9.02 | |||||||
| 11.91% | |||||||
| $0.93 | |||||||
| $1.55 | |||||||
| 9.5% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 45.49 | |||||||
| 0.89 | |||||||
| 1.54 | |||||||
| -0.04% | |||||||
| $186.41 | |||||||
| $668.37 | |||||||
| -5.43% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 17.93 | |||||||
| 3.55 | |||||||
| 3.58 | |||||||
| 4.77% | |||||||
| $20.32 | |||||||
| $41.48 | |||||||
| 12.49% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 23.71 | |||||||
| 1.95 | |||||||
| 2.06 | |||||||
| -0.39% | |||||||
| $0.23 | |||||||
| $0.81 | |||||||
| 1.03% | |||||||
| Prestige Consumer Healthcare Inc | |||||||
| 15.55 | |||||||
| 1.96 | |||||||
| 2.89 | |||||||
| 3.04% | |||||||
| $0.09 | |||||||
| $0.15 | |||||||
| -3.11% | |||||||
| Corcept Therapeutics Inc | |||||||
| 27.23 | |||||||
| 5.43 | |||||||
| 6.03 | |||||||
| 5.22% | |||||||
| $0.03 | |||||||
| $0.14 | |||||||
| 38.95% | |||||||
| Average | |||||||
| 36.8 | |||||||
| 13.37 | |||||||
| 6.79 | |||||||
| 7.71% | |||||||
| $22.08 | |||||||
| $67.9 | |||||||
| 11.37% |